Search ARM

Q1 2019 Data Report


This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

Global Landscape

917+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

Financings

Total Q1 2019 Global Financings

Total Global Financing

$2.2 Billion

 42%

Decrease from Q1 2018

Gene & Gene-modified
Cell Therapy

$2.1 Billion

 78%

Decrease from Q1 2018

Cell Therapy

$823 Million

 89%

Decrease from Q1 2018

Tissue Engineering

$14 Million

 98%

Decrease from Q1 2018

Total Global Financings by Type, by Year

1,060

Clinical trials underway
worldwide by the end of Q1 2019

PH. 1

349

PH. 2

618

PH. 3

93

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

Q1 2019

Gene Therapy
Gene-Modified
Cell Therapy
Cell Therapy
Tissue Engineering

Clinical Trials by Indication: Q1 2019

Report Infographics